PRINCETON, N.J., July 24, 2008 (PRIME NEWSWIRE) -- Pharmacopeia (Nasdaq:PCOP), an innovator in the discovery and development of novel small molecule therapeutics, announced today that it has identified a new lead for advancement in its alliance with GlaxoSmithKline (NYSE:GSK), through its collaboration with the Center of Excellence for External Drug Discovery (CEEDD). This newly identified lead is the first from a program being evaluated as a potential treatment for pain and the fifth lead identified since the alliance was initiated in 2006. As a result of this success, Pharmacopeia will receive a $500,000 milestone payment from GSK.
